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Background: The aquaporins (AQPs), water channel proteins, are known playing a major role in transcellular and
transepithelial water movement; they also exhibit several properties related to tumor development. The aim of the
present study is to elucidate whether the expression of AQP5 is a strong prognostic biomarker for prostate cancer,
and the potential role in the progression of prostate cancer cells.
Methods: AQP5 expression was measured in 60 prostate cancer tissues and cells (both PC-3 and LNCaP) by
immunohistochemistry and immunofluorescence assay. AQP5 gene amplification was detected with FISH (fluorescence
in situ hybridization). Proliferation and migration of cells and AQP5 siRNA cells were detected with MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) and Boyden chambers. Circulating tumor cells (CTCs) were
detected by imFISH staining (CEP8-CD45-DAPI) assay.
Results: The results showed that in 60 tumor specimens, 19 (31.7%) patients showed high level of AQP5 expression,
while 30 (50.0%) showed a moderate, intermediate level of staining, and 11 (18.3%) showed an absence of AQP5
staining, respectively. High-expression of AQP5 protein frequently accompanied gene amplification detection with FISH.
The AQP5 over-expression was also associated with TNM stage (P = 0.042), and lymph node metastasis (P = 0.001). The
relationships between age or tumor size with the expression of AQP5 were not significant (P > 0.05). A positive
correlation between the number of CTCs and AQP5 expression (P < 0.05) was demonstrated. In addition, patients who
were negative for AQP5 had superior cumulative survival rate than those who were positive for it. Over-expression of
AQP5 protein was also found in prostate cancer cells and cell proliferation and migration were significantly attenuated
by AQP5-siRNA.
Conclusions: We concluded that AQP5 in prostate cancer was an independent prognostic indicator. AQP5 over-
expression was likely to play a role in cell growth and metastasis. These conclusions suggest that AQP5 may be an
effective therapeutic target for prostate cancer.
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Prostate cancer (PCa) is the second most frequent cause
of cancer-related deaths among males in the USA [1].
Despite the widespread presence of clinically insignifi-
cant tumors in elderly men, PCa commonly has an ag-
gressive phenotype that requires prompt intervention
[2]. Therefore, it is extremely important to seek novel
targets for therapeutic intervention.* Correspondence: JianpingLi0292@163.com
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unless otherwise stated.Recently, studies have shown that tumor growth, de-
velopment, invasion and metastasis depend on tumor
microenvironment and tumor metabolism. Specifically,
the water balance between the inside and outside of cells
is essential to maintain the malignant epithelial cell
function. Water can permeate the plasma membrane by
simple diffusion, but bulk water flow is mediated by a
channel mechanism through aquaporin (AQP) enzymes
[3]. AQPs belong to a family of water-transporting pro-
teins. Up to now, 13 members of the AQPs have been
identified and can be subdivided into two groups on thehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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water-selective transporters, while AQP3, 7, 9 and 10,
termed aquaglyceroporins, transport water as well as
glycerol and other small solutes [4-6].
The role of AQPs in tumor pathogenesis has been
identified. The study showed that aquaporin 3 was found
to be over-expressed in malignant prostate tissue and
may be involved in tumor progression [7,8]. The expres-
sion of AQP1 is confined to prostate cancer cells and
may be involved in microvascular alteration during
tumor angiogenesis [9]. The over-expression of AQP5
was examined recently and showed that AQP5 is signifi-
cantly associated with cervical cancer, ovarian cancer,
and breast cancer progression [10]. It was shown that
AQP5 plays a key role in cell proliferation. A recent
study showed that AQP5 expression in colorectal cancer
is significantly associated with lung metastasis that is
possibly mediated by the activation of Ras, mitogen acti-
vated protein kinase (MAPK) and Rb signaling pathways
[11]. However, the expression of AQP5 in prostate can-
cer and its clinical significance remain unexplored. To
evaluate the potential of AQP5 as a novel prognostic
marker of prostate cancer, we employed immunohisto-
chemical, immunofluorescence, and FISH methods to
detect the expression and amplification of AQP5 gene in
clinical samples and prostate cancer cells, and immuno-
fluorescence in situ hybridization (imFISH) staining to
detect CTCs. We first analyzed the correlations between
the expression of AQP5 and clinicopathologic features,
CTCs, and prognosis of prostate cancer. Then, we also
analyzed the effects of AQP5 knockdown on the cell
proliferation and migration with 3-(4,5-dimethylthiazol-2-




From January 2009 to June 2013, 60 patients were re-
cruited from the Department of Urology Surgery, Sec-
ond Affiliated Hospital of the Xi’an Jiaotong University.
Samples were fixed with 4% formalin for histological
studies. Of the 60 patients, median age at the time of
surgery was 56.7 years (range 40 to 76 years). Tumor
stage was recorded according to the classification of the
International Union against Cancer (TNM stage). There
were 7 patients with stage I tumors, 22 with stage II, 27
with stage III, and 4 with stage IV. All patients under-
went operative surgical therapy, including partial resec-
tion or radical excision at the Department of Urinary
Surgery, Second Affiliated Hospital of the Xi’an Jiaotong
University. All patients were followed up and the median
duration of follow-up was 23 months (4 to 52 months).
All the studies were approved by the Human Subjects
Committee of the Xi’an Jiaotong University, China.Written informed consent was obtained from the patient
for the publication of this report and any accompanying
images
Cell culture
PC-3 and LNCaP prostate cancer cell lines (obtained
from the American Tissue Type Collection, USA) were
maintained in DMEM (GIBCO, Grand Island, NY, USA)
and 10% heat-inactivated FBS and incubated in 5% CO2
humidified atmosphere at 37°C. Cells were grown to
80% confluency prior to treatment.
Immunohistochemistry
AQP5 protein was detected immunohistochemically using
a standardized streptavidin-peroxidase (SP) method. Tis-
sue sections (4 μm) were incubated overnight with pri-
mary monoclonal antibody (1:100 dilution). Then the
slides were incubated for 30 minutes with biotinylated
goat anti-rabbit IgG (1:200 dilution). Color was developed
using 0.02% 3,3’-diaminobenzidine (DAB) for 5 to 7 mi-
nutes. Negative controls for immunostaining replaced the
primary antibody with nonimmune goat or rabbit serum.
The staining was scored semiquantitatively as negative (0;
no staining or < 10% staining), moderate (1; either diffuse
weak staining or strong staining in less than 30% of cells
per core), or strong (2; defined as strong staining of 30%
or more of the cells). The antibodies against AQP5, and β-
actin were purchased from Santa Cruz Biotechnology
(Santa Cruz, CA, USA).
Immunofluorescence assay
Tissue sections (4 μm) were incubated overnight. Slides
were incubated with CY3-labeled anti-AQP5 (1:100)
overnight. Fluorescent imaging was obtained with a con-
focal laser scanning microscope (Carl Zeiss MicroIma-
ging, Inc., Thornwood, NY, USA). Exponentially growing
cells were seeded on 25-mm square glass cover slips.
Cells were fixed with 4% formaldehyde for 5 minutes,
permeabilized with 0.2% solution of Triton X-100 in
PBS, and blocked with 2% BSA-PBS for 30 minutes.
Slides were incubated with CY3- or FITC-labeled anti-
AQP5 (1:100) overnight, respectively. Cell nuclei were
counterstained by 4’,6-diamidino-2-phenylindole (DAPI).
Fluorescent imaging was obtained with a confocal laser
scanning microscope (Carl Zeiss MicroImaging, Inc.,
Thornwood, NY, USA).
Fluorescence in situ hybridization
AQP5 gene amplification was detected with dual-color
fluorescence in situ hybridization (FISH) using a Passvi-
sion AQP5 DNA probe kit (Vysis Inc. Downers Grove, IL,
USA) according to its manufacturer’s instructions. Sec-
tions were baked overnight at 56°C, and were then depar-
affinized followed by enzyme digestion and fixation. The
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ard saline citrate. After a buffer wash, 10 μl of a mixture of
two directly labeled probes were added and hybridization
was carried out at 37°C for 14 to 18 hours. The slides were
then counterstained with DAPI, mounted, and stored
in the dark before signal enumeration. AQP5-spectrum
red probe contains a DNA sequence specific for the
AQP5 gene. CEP17 (chromosome enumeration probe
17)/spectrum green probe containing alpha-satellite DNA
that hybridizes to the D17Z1 locus (centromere region of
chromosome 17) was used as a control. Gene amplifica-
tion was scored when a minimum of 20 cancer cell nuclei
exhibited AQP5/CEP17 ratio ≥ 2, or when AQP5 signal
cluster was observed.
Cell viability assay
Cells were seeded (5 × 103/well) in 96-well plates and
cultured overnight. Then the MTT assay was used to de-
termine cell viability. siRNA was added to the cells and fur-
ther cultured for 24 hours. Then, MTT reagent (5 mg/ml)
was added and incubation continued for an additional
4 hours. The reaction was terminated with 150 μl of
dimethylsulfoxide (DMSO, Sigma-Aldrich, St Louis, MO,
USA) per well. Absorbance values were determined using
an MRX Revelation 96-well multiscanner (Dynex Tech-
nologies, Chantilly, VA, USA).
RT-PCR (Reverse transcription-polymerase chain reaction)
Total RNA from cells was isolated using TRIzol reagent
(GIBCO BRL, Grand Island, NY, USA). First-strand
cDNA was synthesized from 2 μg of total RNA using the
RevertAid Kit. The PCR primers that were used for the
detection of AQP5 was synthesized as follows: 5’-CAG
CTG GCA CTC TGC ATC TT-3’ (sense) and 5’-TGA
ACC GAT TCA TGA CCA CC-3’ (antisense) and 5’-
ATC GTG CGT GAC ATT AAG GAG AAG-3’ (sense)
and 5’-AGG AAG AAG GCT GGA AGA GTG-3’ (anti-
sense) for β-actin (179 bp). The PCR conditions were as
follows: one cycle of denaturing at 94°C for 3 minutes,
followed by 35 cycles at 94°C for 30 seconds, 55°C for 30
seconds, and 72°C for 35 seconds before a final exten-
sion at 72°C for 5 minutes.
Western blotting
Briefly, 5 × 105 cells were incubated on ice for 30 mi-
nutes in 0.5 ml of ice-cold whole-cell lysate buffer. The
protein content of the cell was determined, and the cel-
lular lysates were separated by 10% SDS-PAGE, and
electro-transferred onto nitrocellulose membranes. After
being blocked with 5% non-fat milk in tris-buffered sa-
line and Tween (TBST), the membranes were incubated
with primary antibodies at 4°C overnight, followed by
secondary antibody for 2 hours. Immunoreactive bands
were visualized using an enhanced chemiluminescencekit (Amersham Pharmacia Biotech, Piscataway, NJ, USA).
The Western blot signals were quantitated by densitomet-
ric analysis using Total Lab Nonlinear Dynamic Image
analysis software (Nonlinear, Durham, NC, USA).
siRNA assay
To inhibit the expression of AQP5, we used siRNA
oligonucleotide sequence: 5’-CGG UGG UCA UGA
AUC GGU UTT-3’ (sense) and 5’-AAC CGA UUC AUG
ACC ACC GCA-3’ (antisense). The oligonucleotides for
negative siRNA were synthesized as sense 5’-UUC UCC
GAA CGU GUC ACG UTT-3’, antisense 5’-ACG UGA
CAC GUU CGG AGA ATT-3’. The PC-3 cells (2 × 106)
were transfected with siRNA targeted against AQP5
(100 nm/l) or a control siRNA (Qiagen, Valencia, CA,
USA) using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA). Cells were covered overnight before starvation.
Cell invasion assay
Cell invasion assay was performed by employing Boyden
chambers coated with 50 μg/ml of Matrigel solution.
The cells were first seeded in 12-well plates at a concen-
tration of 2.5 × 105 per well and were cultured for 48
hours. The Matrigel invasion chamber was incubated for
24 hours in a humidified tissue culture incubator. After
24 hours, the noninvasive cells were removed from the
upper surface of the separating membrane by gentle
scrubbing with a cotton swab, and the invading cells
were fixed in 100% methanol and stained with 0.1% crys-
tal violet solution. They were then counted under a
microscope at 200× magnification.
Blood sampling and enrichment of circulating tumor cells
Seven and half milliliters of peripheral blood collected in
BD Vacutainer tube (Becton, Dickinson and Company,
Franklin, NJ, USA) were washed with PBS. All samples
were collected after discarding the first 2 ml of blood.
Red blood cells were removed. Resulting cell pellet was
resuspended in PBS and subsequently incubated with 0.5
ml of antileukocyte surface marker CD45 monoclonal
antibody coated magnetic beads for 30 minutes, followed
by separation of magnetic beads using a magnetic stand
(Promega, Madison, WI, USA). Supernatants were trans-
ferred into a new tube, and subsequently centrifuged at
800 g for 3 minutes. Cell pellets were spotted on glass
slides, and then followed with imFISH (immuno- fluor-
escence in situ hybridization) staining.
imFISH staining (CEP8-CD45-DAPI)
Tumor cells were negative enriched by immunomagnetic
beads method, followed by identification with cytology
analysis. FISH was performed using centromere DNA
probes of chromosome 8 (yellow) (Vysis Inc. Downers
Grove, IL, USA), and immunofluorescence assay was
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nology Inc., Santa Cruz, CA, USA). The slides were
washed three times with TBS. Cells were mounted
with mounting medium containing the nuclear dye
DAPI. A blinded review of the fluorescent images by
three technicians confirmed the identity of the CTCs
from 3-color fluorescent images that were magnified
x400. Evaluation criteria for CTC identification from
fluorescent images included both CEP8 ≥ 3 and CD45
(−) staining pattern overlying the DAPI staining of the
nucleus.
Statistical analysis and patient outcome
Data were analyzed by chi-square test (χ2) or two-sided
Fisher’s exact test, as appropriate. Pearson correlation
coefficient was used to measure the strength of the asso-
ciation among AQP5 gene amplification. Survival rate
was calculated by the Kaplan-Meier method, and differ-
ences were examined by the log-rank test. Factors found
to be significant were then selected for a stepwise Cox’s
multivariate proportional hazard model to determine their
prognostic values. P < 0.05 was considered statistically
significant. All statistical analyses were performed using
SPSS Version 13.0 statistical software (SPSS, Chicago,
IL, USA).Figure 1 Representative results of aquapore 5 (AQP5) expression by
in situ hybridization (FISH) (C). (A) Normal tissue negative for AQP5 expr
tissue with intense AQP5 expression. Paraffin sections were immunostained
AQP5 in prostate tissue: fluorescent imaging was obtained with a confocal
signal in the cancer group, the control, and the paraneoplastic group. (C) A
cancer group is amplified compared to the control and paraneoplastic groResults
Protein expression and gene amplification of AQP5 in
prostate cancer
To examine the expression status of AQP5 in prostate
cancer, we first used immunohistochemical evaluation.
The results highlight the difference observed in AQP5
immunostaining in the compartment (Figure 1A). In 19/
60 (31.7%) patients, AQP5 expression was strong and in
30/60 (50.0%) patients AQP5 expression was moderate
in the cancer group. AQP5 expression was only occa-
sionally detected in paraneoplastic 11/60 (16.7%) and
normal tissues 8/60 (13.3%).
To further determine AQP5 expression, prostate tissue
was stained with fluorescence immunostaining and ana-
lyzed by confocal microscopy. The results showed that
AQP5 fluorescence signal is substantially increased in
the cancer group compared to the paraneoplastic and
normal group (Figure 1B). The above results further sug-
gest that AQP5 is over-expressed in prostate cancer.
Because FISH is a more accurate and sensitive assay
(usually regarded as the gold standard) for detecting
gene amplification compared to gene expression using
immunohistochemistry, we further detected AQP5 amp-
lification status using FISH. Interestingly, strong AQP5
expression had a positive correlation with AQP5 geneimmunostain (A), immunofluorescence (B), and fluorescence
ession, paraneoplastic tissue negative for AQP5 expression, and tumor
as described in the Methods section. (B) Immunofluorescence of
laser scanning microscope. From top to bottom, AQP5 fluorescence
QP5 gene amplification status was detected using FISH. AQP5 gene in
up. Con: control, P: paraneoplastic, Ca: cancer.
Table 2 Association between aquapore 5 (AQP5) protein
expression and clinicopathologic factors in prostate cancers
AQP5
Variables Case 2 1 0 P-value
n = 60 19 (%) 30 (%) 11 (%)
Age (years) 0.785
> 60 36 13 (36.1) 16 (44.4) 7 (19.4)
≤ 60 24 6 (37.5) 14 (58.3) 4 (16.7)
Tumor size 0.929
≤ 2 cm 32 10 (31.3) 16 (50.0) 6 (18.8)
> 2 cm 28 9 (32.1) 14 (50.0) 5 (17.9)
Lymph node metastasis 0.001
Negative 22 2 (9.1) 10 (45.5) 10 (45.5)
Positive 38 17 (44.7) 20 (52.6) 1 (2.6)
ABCD stage 0.042
I/II 29 5 (17.2) 16 (55.2) 8 (27.6)
III 27 10 (37.0) 14 (50.0) 3 (1.1)
IV 4 4 (100.0) 0 (0.0) 0 (0.0)
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In contrast, the expression of AQP5 was weak or absent
where the AQP5 gene was not amplified.
Relationships between AQP5 expression and
clinicopathological parameters
Table 2 summarizes the associations of AQP5 protein
expression and the clinicopathological parameters of
prostate cancer. The strong expression of AQP5 was
seen in 5 of 29 stage I to II cases (17.2%) and was signifi-
cantly lower than that in stage III (37.0%, 10 of 27 cases)
and stage IV (100.0%, 4 of 4 cases) cases (P < 0.05).
AQP5 expression was also associated with lymph node
metastasis (P = 0.001). We also investigated the relation-
ship between age, tumor size with expression of AQP5,
however, but no significant relationships were observed
between these factors (P > 0.05).
Prognostic value of AQP5 in patients with prostate cancer
In order to determine the prognostic value of AQP5 for
prostate cancer, we analyzed the cumulative survival of
patients according to their AQP5 status (Figure 2). The
AQP5-weak and non-staining specimens were merged as
AQP5-negative, and strongly staining was regarded as
AQP5-positive. The cumulative survival rate in AQP5-
negative patients (n = 41) at 3 years was 64.3% (n = 26.4
median time 65.2 months). In contrast, the cumulative
survival rate in AQP5-positive patients (n = 19) was
23.2% (n = 4.4 median time 20.7 months), a difference
that is highly statistically significant (P < 0.05).
Multivariate analysis in our study revealed that lymph
node metastasis (P = 0.048) and ABCD stage (P = 0.037)
were the independent prognostic factors for overall
survival time in patients with prostate cancer. Tumor
diameter and other clinical parameters were also not in-
dependent prognostic factors.
Expression of AQP5 correlates with CTCs enumeration
CTCs are shed from the primary tumor into the circula-
tion. This has long been associated with metastasis and
poor survival. In view of the obvious clinical relevance,
CTCs have been recently recommended by the American
Society of Clinical Oncology as an acceptable cancerTable 1 Relationship between protein expression of
aquapore 5 (AQP5) and gene amplification
AQP5
Gene Case 0 1 2 P-value
n = 60 11 (%) 30 (%) 19 (%)
AQP5 0.009
Amplification 34 0 (0.0) 17 (56.7) 17 (89.5)
Normal 26 11 (100.0) 13 (43.3) 2 (10.5)marker. To further determine whether or not AQP5 is an
adverse prognostic biomarker, the correlation between
AQP5 expression and the number of CTCs was analyzed.
CTCs were detected in 65.00% (13/20) of prostate cancer
patients with strong AQP5 expression versus 30.00%
(12/40) with low and absent AQP5 expression (P < 0.05;
Figure 3).
AQP5 expression in prostate cancer cells
To further determine AQP5 expression in prostate
cancer cells, PC-3 and LNCaP cells were stained with
fluorescence immunostaining and analyzed by confocalFigure 2 Kaplan-Meier analysis of the overall postoperative
survival curves in prostate cancer cases according to their
immunohistochemical staining as positive or negative for
aquapore 5 (AQP5).
Figure 3 Circulating tumor cells (CTCs) were stained with anti-CD45-CEP8-DAPI in peripheral blood of prostate cancer patients (×400).
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negative control and human lung cancer cell line A549,
the AQP5-expressing cancer cell line was used as a posi-
tive control for AQP5 expression. Immunoblotting ana-
lysis revealed that both prostate cancer cell lines express
AQP5 protein (Figure 4). AQP5 fluorescence signal in
PC-3 is substantially stronger than LNCaP, so this cell
was used for the further study.Figure 4 Immunodetection of aquapore 5 (AQP5) proteins in PC-3 an
was used as a negative control and human lung cancer cell line A549 was
was obtained with a confocal laser scanning microscope. AQP5 fluorescencProliferation and migration of PC-3 cells were inhibited in
response to AQP5 silencing
To examine whether AQP5 expression plays a role in
the progression of prostate cancer, proliferation and mi-
gration of prostate cancer cells were examined in re-
sponse to siRNA-mediated knockdown of AQP5. AQP5
mRNA and protein expression in PC-3 cell was signifi-
cantly decreased by AQP5 siRNA transduction. Thed LNCaP PCa (prostate cancer) cells. The endothelial cell ECV-304
used as a positive control for AQP5 expression. Fluorescent imaging
e signal in PC-3 is stronger than in the LNCaP cell.
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PC-3 cell was significantly decreased with AQP5 silen-
cing. Moreover, the number of migrated PC-3 cells was
significantly decreased in response to AQP5 silencing
(Figure 5).
Discussion
Prostate cancer is one of the most aggressive and in-
tractable malignant tumors, and its incidence and mor-
tality have also rapidly increased in the United States
[12]. Unfortunately, the mechanisms contributing to its
carcinogenesis and progression are still poorly understood.Figure 5 Inhibition of cell proliferation and migration of PC-3 cell in r
siRNA for knockdown of AQP5 mRNA was confirmed by PCR. (B) The effica
Western blotting. (C) Quantification of mRNA. (D) Quantification of protein
AQP5 silencing on the invasion of PC-3 cells. Data from at least three indep
means ± SEM. *P < 0.05 was considered statistically significant. (G): ColumnsIn the present study, we aimed to determine the clinical
significance of AQP5 expression in prostate cancer pa-
tients. AQP5, as a water channel protein, is also a pre-
dictor of early tumor recurrence, lymph node metastasis,
and poor clinical outcome in cancer patients [13]. Our re-
sults revealed that AQP5 is up-regulated in prostate can-
cer and this expression is accompanied by AQP5 DNA
amplification. AQP5 protein was also expressed in pros-
tate cancer cell lines, PC-3 and LNCaP. Our results also
suggested that AQP5 is closely correlated with advanced
TNM stage, CTCs, and poor prognosis. Cell culture exper-
iments also revealed the role of AQP5 in tumor cellesponse to aquapore 5 (AQP5) silencing. (A) The efficacy of AQP5
cy of AQP5 siRNA for knockdown of AQP5 protein was confirmed by
. (E) Effect of AQP5 silencing on the viability of PC-3 cells. (F) Effects of
endent experiments with duplicate determinations are expressed as
in the graph are the diagram of the count analysis.
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derstanding of AQP5 role as a negative prognostic marker.
Aquaporins (AQPs) are a family of small membrane
transport proteins [14]. Compelling new evidence has
implicated several members of the AQP family, includ-
ing AQP5, in tumorigenesis. Moreover, intensive studies
have been focused on the modulation of AQP5 expres-
sion in tumor cells and its effects on tumorigenesis,
tumor growth and progression [15-18]. AQP5, a 21 to
24 kDa protein, is a component of caveolae, invaginated
microdomains of the plasma membrane. AQP5 was ini-
tially described as the main structural protein in caveo-
lae and was believed to be a key molecule involved in
oncogenic transformation and malignant progression
[11]. AQP5 plays an important regulatory role in several
signaling pathways in cellular transformation, including
those mediated by the Src family of tyrosine kinases, epi-
dermal growth factor receptor, protein kinase C, Wnt,
and Erk1/2 [10]. AQP5 has been suggested to act either
as a tumor suppressor or as an oncogene, depending on
the tumor type. These various effects may be explained
by the activation status of different domains of AQP5 or
the expression levels of other molecules that interact
with AQP5 in these different signaling pathways [19].
Recently, Lee et al. reported that AQP5 over-expression
was significantly associated with lymph node involve-
ment and a poorer prognosis in patients with breast can-
cer [13]. Huang et al. also verified that AQP5 promoted
the proliferation and migration of human gastric carcin-
oma cells. Interestingly [20], Fischer et al. performed dif-
ferential display to find that AQP5 was expressed only in
normal colonic tissue and not, or to a lesser extent, in
cancer cells [21]. The clinical significance of AQP5 in
prostate cancer remains largely unexplored. Our results
showed that AQP5 was mainly expressed in prostate
cancer cells. The expression patterns of AQP5 in pros-
tate tissues that we detected are consistent with the re-
sults of previous studies [6,10,11,22]. Furthermore, we
determined that high levels of expression of AQP5 were
correlated with gene amplification in our limited cases
study, which is the first reported in prostate cancer. In
addition, in the present study, we also demonstrated sig-
nificantly decreased cell proliferation and migration of
prostate cancer cells with AQP5 silencing. Osmolar
changes have been revealed to affect cell proliferation, as
previously demonstrated by the negative effect of hyper-
tonicity on cell proliferation [23]. Tumor cells bind to
the basal membrane surface, and the formation of pseu-
dopodial protrusions at the leading edge of migrating
cells is the earliest step in locomotion. Studies have sug-
gested that AQP-facilitated water permeability in cell
protrusions enhances their formation and thus the rate
of cell migration. AQP expression and tumor cell water
permeability are potentially important determinants fortumor spread and metastasis [24-26]. However, the pos-
sibility that AQP5 may promote cancer cell migration by
other mechanisms could not be excluded. Further stud-
ies are required to elucidate the specific underlying mo-
lecular mechanisms.
CTCs are tumor cells shed from the primary tumor
into the circulation. The presence of CTCs in the per-
ipheral blood of patients has long been associated with
metastasis and poor survival and is now considered an
acceptable cancer marker. Yet, current techniques are
limited [27,28]. The only commercially available CTC
test (CellSearch; Veridex LLC, North Raritan, NJ, USA)
has a detection rate of 50% in late-stage patients [29,30].
In the current study, we detected CTCs harboring nega-
tive enrichment using an immunomagnetic beads method,
followed by identification with cytologic analysis, im-
munofluorescence, and imFISH. This combination of
methods resulted in detection rates up to 65.00% in pa-
tients with AQP5 over-expression, suggesting that imFISH
staining could be used as a detection method for CTCs in
future studies. In addition, our study verified that AQP5
over-expression is associated with the likelihood of metas-
tasis compared to lower expression of AQP5.
Conclusions
The AQP5 protein is up-regulated in prostate cancer
and is closely related to advanced ABCD stage, lymph
node metastasis, CTCs and poor prognosis. Moreover,
AQP5 expression was associated with cell proliferation
and migration. Although the mechanisms require further
elucidation, AQP5 might be used as a novel biomarker
for prostate cancer aggressiveness.
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